样式: 排序: IF: - GO 导出 标记为已读
-
Incidence trends for common subtypes of T-cell lymphoma in Taiwan and the United States from 2008–2020 Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-17 Chung-I Huang, Chien-Yu Ker, Hung-Ju Li, Yu-Ting Hsiao, Sheng-Fung Lin, Yu-Chieh Su
-
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-16
Abstract We conducted a multi-institutional retrospective study in 100 transplant-ineligible (TI) patients with diffuse large B-cell lymphoma (DLBCL) that relapsed or progressed after first-line R-CHOP (or -like) therapy to develop a robust predictive model for TI relapsed/refractory (r/r) DLBCL, which has a heterogeneous but poor prognosis by currently available treatment modalities other than chimeric
-
Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-16 Jun Takizawa, Ritsuro Suzuki, Koji Izutsu, Toru Kiguchi, Hideki Asaoku, Yoshio Saburi, Taro Masunari, Atae Utsunomiya, Kengo Takeuchi, Naoya Nakamura, Koichi Ohshima, Michaela Gruber, Ulrich Jäger, Sadao Aoki, Junji Suzumiya
-
Evaluation of the pathogenic potential of germline DDX41 variants in hematopoietic neoplasms using the ACMG/AMP guidelines Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-16 Hirotaka Matsui, Makoto Hirata
Clinical use of gene panel testing for hematopoietic neoplasms in areas, such as diagnosis, prognosis prediction, and exploration of treatment options, has increased in recent years. The keys to interpreting gene variants detected in gene panel testing are to distinguish between germline and somatic variants and accurately determine whether the detected variants are pathogenic. If a variant is suspected
-
A case of Bloom syndrome manifesting with therapy-related myelodysplastic syndromes harboring a novel BLM gene variant Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-15 Takuma Ohashi, Hiroyoshi Kunimoto, Jun Nukui, Haruka Teshigawara, Satoshi Koyama, Takuya Miyazaki, Maki Hagihara, Kenji Matsumoto, Eriko Koshimizu, Naomi Tsuchida, Haruka Hamanoue, Satoko Miyatake, Akihiro Yachie, Naomichi Matsumoto, Hideaki Nakajima
-
Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-09 Hirozumi Sano, Keitaro Fukushima, Michihiro Yano, Shinya Osone, Yoko Kato, Daiichiro Hasegawa, Takako Miyamura, Shotaro Iwamoto, Hiroyuki Takahashi, Kiminori Terui, Akio Tawa, Daisuke Tomizawa
-
Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-08 Kensuke Usuki, Takuro Kameda, Noriaki Kawano, Tomoki Ito, Yoshinori Hashimoto, Kotaro Shide, Hiroshi Kawano, Masaaki Sekine, Takanori Toyama, Hiromitsu Iizuka, Seiichi Sato, Masanori Takeuchi, Junzo Ishizaki, Kouichi Maeda, Michikazu Nakai, Kiyoshi Yamashita, Yoko Kubuki, Kazuya Shimoda
-
Numerous osteoclasts and osteoblasts in the bone marrow due to hyperparathyroidism Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-06 Yi Feng, Tao Wang
-
Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-05
Abstract Objective To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes. Methods Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1
-
Decade-long WT1-specific CTLs induced by WT1 peptide vaccination Int. J. Hematol. (IF 2.1) Pub Date : 2024-03-01 Tatsuya Suwabe, Yasuhiko Shibasaki, Suguru Tamura, Takayuki Katagiri, Kyoko Fuse, Tori Ida-Kurasaki, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko
-
First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-29 Yuka Shiozawa, Shinya Fujita, Yasuhito Nannya, Seishi Ogawa, Naho Nomura, Toru Kiguchi, Nobuo Sezaki, Himari Kudo, Takaaki Toyama
-
Predictive factors for l-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-29 Chane Choed-Amphai, Jiraporn Khorana, Lalita Sathitsamitphong, Rungrote Natesirinilkul, Pimlak Charoenkwan
-
The pathogenesis of cancer-associated thrombosis Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-29 Kohei Tatsumi
-
Influence of FOXP3 single-nucleotide polymorphism after allogeneic hematopoietic stem cell transplantation Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-28 Kai Kuroiwa, Misuzu Sato, Hinako Narita, Reiko Okamura, Yuka Uesugi, Yohei Sasaki, Shotaro Shimada, Megumi Watanuki, Shun Fujiwara, Yukiko Kawaguchi, Nana Arai, Kouji Yanagisawa, Keiichi Iezumi, Norimichi Hattori
-
Prevalence of thalassemia-carrier couples and fertility risk assessment Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-27 Liu-Song Wu, Xi Luo, Mei Tan, Li-Jun Zhang, Hong-Fang Luo, Ge Huang, Pei Huang, Jindong Chen, Yan Chen
-
Long-term lymphocyte subset number reconstitution is unique but comparable between umbilical cord blood and unrelated bone marrow transplantation Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-26 Keiko Tsumita, Shinsuke Takagi, Yuki Asano-Mori, Otoya Watanabe, Michiho Shindo, Kyosuke Yamaguchi, Mitsuhiro Yuasa, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Hisashi Yamamoto, Hideki Araoka, Go Yamamoto, Shigeyoshi Makino, Atsushi Wake, Naoyuki Uchida, Shuichi Taniguchi, Yukako Koike
-
Progress in medical therapy in aplastic anemia: why it took so long? Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-26
Abstract The treatment of aplastic anemia (AA) has significantly advanced in the last 50 years, evolving from a fatal condition to one where survival rates now exceed 80–85%. Hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have become the primary treatments, with the latter widely adopted due to factors like the scarcity of compatible donors, patient age, comorbidities
-
Effects of human herpesvirus 6B reactivation on cognitive function in cord blood transplant recipients: a prospective multicenter study Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-26 Masao Ogata, Kumi Oshima, Kuniko Takano, Rie Kawano, Yasunori Ueda, Takashi Imamura, Yukinori Nakamura, Takahiro Okada, Tomomi Toubai, Toshimitsu Ueki, Nobuhiko Uoshima, Hiroyuki Ishida, Akihito Shinohara, Sachiko Seo, Takahiro Fukuda, Masatoshi Inagaki
-
Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-22 Yasuhisa Yokoyama
The treatment of acute promyelocytic leukemia (APL) has evolved with the introduction of all-trans retinoic acid (ATRA) and subsequent arsenic trioxide (ATO), particularly in standard-risk APL with an initial white blood cell count (WBC) < 10,000/μL, where a high cure rate can now be achieved. However, for some patients with risk factors, early death or relapse remains a concern. Insights from the
-
Measurement of serum hepcidin-25 by latex agglutination in healthy volunteers and patients with hematologic disorders Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-19 Hiroshi Kawabata, Naoki Miyazawa, Yumi Matsuda, Misaki Satobe, Yasushi Mizogami, Yoko Kuriyama, Tomomi Sakai, Minako Mori, Michio Sasa
-
Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-16 Takayuki Nakamura, Shuki Oya, Hidetoshi Ozawa, Yoshimi Maehiro, Seiya Muta, Masahiro Umeda, Yusuke Takaki, Toshinobu Fukuyama, Yoshitaka Yamasaki, Maki Yamaguchi, Kazutoshi Aoyama, Fumihiko Mouri, Yoshiki Naito, Koji Nagafuji
-
Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-13
Abstract Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease 2019 (COVID-19) have a poor prognosis, as noted in several case reports of recipients who had COVID-19 before the infusion. We report the case
-
Dysregulated hemostasis in acute promyelocytic leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-11 Yohei Hisada
-
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-09 Osamu Kumano, Shinya Suzuki, Masako Yamazaki, Yoshimori An, Masahiro Yasaka, Masahiro Ieko
-
Aplastic anemia: history and recent developments in diagnosis and treatment Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-04
Abstract Acquired aplastic anemia is an immune-mediated disease that targets hematopoietic stem cells, which is diagnosed by findings of peripheral blood pancytopenia and hypocellular bone marrow. Although the diagnostic definition is simple, differential diagnosis from other overlapping hematopoietic disorders such as hypoplastic myelodysplastic syndrome and inherited bone marrow failure syndrome
-
Cancer-associated thrombosis and bleeding Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-04 Takayuki Ikezoe
-
Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma Int. J. Hematol. (IF 2.1) Pub Date : 2024-02-01 Masato Yanagi, Makiko Mori, Mamoru Honda, Yuichi Mitani, Masafumi Seki, Kohei Fukuoka, Koichi Oshima, Yuki Arakawa, Katsuyoshi Koh
-
Histiocytic sarcoma following CAR T-cell therapy: a case report Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-31
Abstract Background Development of secondary tumor after CART treatment is not well investigated. We report a pediatric B-cell acute lymphoblastic leukemia (B-ALL) patient who developed histiocytic sarcoma shortly after CART therapy. Case report: A 9-year-old boy diagnosed with relapsed B-ALL presenting the KRAS A146T mutation received autologous mouse-derived CD19 and CD22 chimeric antigen receptor
-
Diffuse large B-cell lymphoma of the skull vault Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-30 Satoshi Ichikawa, Hisayuki Yokoyama, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae
-
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-29 Alexandre Benoit, Madelyn J. Abraham, Sheena Li, John Kim, Roger Estrada-Tejedor, Rowa Bakadlag, Nivetha Subramaniam, Kiran Makhani, Cynthia Guilbert, Raymond Tu, Matthew Salaciak, Kathleen Oros Klein, Krysta Mila Coyle, Laura K. Hilton, Raoul Santiago, Svetlana Dmitrienko, Sarit Assouline, Ryan D. Morin, Sonia V. del Rincon, Nathalie A. Johnson, Koren K. Mann
-
Cancer-associated thrombosis in hematologic malignancies Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-25 Masahiko Fukatsu, Takayuki Ikezoe
-
TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-25 Hideaki Ueki, Chitose Ogawa, Hiroaki Goto, Masanori Nishi, Junko Yamanaka, Shinji Mochizuki, Takuro Nishikawa, Tadashi Kumamoto, Ritsuo Nishiuchi, Atsushi Kikuta, Shohei Yamamoto, Shunji Igarashi, Atsushi Sato, Toshinori Hori, Akiko M. Saito, Tomoyuki Watanabe, Takao Deguchi, Atsushi Manabe, Keizo Horibe, Hidemi Toyoda
-
A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-25
Abstract Background Recombinant human soluble thrombomodulin (rhTM) is commonly used in Japan to treat disseminated intravascular coagulation (DIC), but its efficacy compared with other anticoagulants is unclear. We conducted a systematic review and meta-analysis to investigate this issue in DIC patients with hematological malignancies. Methods We searched PubMed, Cochrane, and Scopus for prospective
-
Differences between Japanese new criteria and pregnancy-specific modified ISTH DIC scores for obstetrical DIC diagnosis Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-23 Mamoru Morikawa, Akio Kamiya, Aya Yoshida, Shuhei Nishibata, Hidetaka Okada
-
Multiple myeloma presenting as nodular hepatic lesions mimicking hepatocellular carcinoma Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-22 Naonori Harada
-
Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-22 Yusuke Okayama, Naonori Harada, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Hiroshi Okamura, Asao Hirose, Mika Nakamae, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Masayuki Hino, Hirohisa Nakamae
-
Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-22
Abstract Hyperthermia is a unique treatment option for cancers. Multiple myeloma (MM) remains incurable and innovative therapeutic options are needed. We investigated the efficacy of hyperthermia and carfilzomib in combination against MM cells. Although MM cell lines exhibited different susceptibilities to pulsatile carfilzomib treatment, mild hyperthermia at 43℃ induced MM cell death in all cell lines
-
Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-21 Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda, Tomoko Maruhashi, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Masafumi Nakamura, Yusaku Maeda, Tomoyo Hara, Hiroki Yamagami, Shiro Fujii, Kumiko Kagawa, Shuji Ozaki, Kiyoe Kurahashi, Itsuro Endo, Ken-ichi Aihara, Emiko Nakaue, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Masahiro Abe
-
Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-19 Naoshi Obara, Kensuke Usuki, Takeshi Hayashi, Masato Fujii, Takayuki Ikezoe
-
Knockdown of the Shwachman-Diamond syndrome gene, SBDS, induces galectin-1 expression and impairs cell growth Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-19 Masafumi Yamaguchi, Yukihiro Sera, Hanae Toga-Yamaguchi, Hirokazu Kanegane, Yusuke Iguchi, Kingo Fujimura
-
A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-18 Kana Kato, Shinsuke Takagi, Hirofumi Takano, Shinichi Tsunoda, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Yukako Koike, Shigeyoshi Makino, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida
-
HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analysis Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-17 Keiko Fukunaga, Kazuhiro Ikegame, Hirohisa Nakamae, Noriko Doki, Takahiro Fukuda, Yukio Kondo, Takahide Ara, Tetsuya Eto, Yasuo Mori, Ken-ichi Matsuoka, Yoshinobu Kanda, Makoto Onizuka, Yoshiko Atsuta, Tatsuo Ichinohe, Satoko Morishima, Junya Kanda
-
Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-17 Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Yusuke Saigusa, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima
-
Anticoagulant effects of protein C, protein S, and antithrombin levels on the protein C pathway in young children Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-16
Abstract The protein C (PC) pathway involves physiological anticoagulant factors (PC, protein S [PS], and factor V) and performs major anticoagulant functions in adults. Variations in overall PC pathway function due to dynamic changes in PC and PS in early childhood are poorly understood. We aimed to evaluate the contributions of PC pathway function during early childhood by measuring changes in plasma
-
HLA-haploidentical T-cell receptor αβT/B-cell-depleted stem cell transplantation for Fanconi anemia Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-16 Akihiro Iguchi, Toru Uchiyama, Kentaro Fujimori, Yoshihiro Gocho, Hirotoshi Sakaguchi, Takao Deguchi, Daisuke Tomizawa, Ken-Ichi Imadome, Masafumi Onodera, Kimikazu Matsumoto
-
Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-09 Dai Maruyama, Ai Omi, Fumi Nomura, Tokiko Touma, Yukiko Noguchi, Kyoko Takebe, Koji Izutsu
-
Auer rods in mature granulocytes in peripheral blood Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-04 Enrico Schalk, Antje-Friederike Pelz
-
Characteristics and prognosis of patients with COVID-19 and hematological diseases in Japan: a cross-sectional study Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-03
Abstract The Japanese Society of Hematology performed an observational cross-sectional study to clarify the morbidity, prognosis, and prognostic factors in patients with COVID-19 with hematological diseases (HDs) in Japan. The study included patients with HDs who enrolled in our epidemiological survey and had a COVID-19 diagnosis and a verified outcome of up to 2 months. The primary endpoints were
-
Abnormal bone marrow T1-weighted MRI images in a pediatric patient with acute lymphoblastic leukemia without peripheral blasts Int. J. Hematol. (IF 2.1) Pub Date : 2024-01-03 Momoko Oyake, Yuka Hirakuni, Naoki Hirano, Souichi Suenobu, Kenji Ihara
-
Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-27 Shinichi Makita, Shuichi Ota, Yuko Mishima, Kensuke Usuki, Daisuke Ennishi, Masamitsu Yanada, Noriko Fukuhara, Ryusuke Yamamoto, Atsushi Takamine, Go Nohara, Koji Izutsu
-
SPAG6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-26
Abstract Adult B-cell acute lymphoblastic leukemia (B-ALL) prognosis remains unsatisfactory, and searching for new therapeutic targets is crucial for improving patient prognosis. Sperm-associated antigen 6 (SPAG6), a member of the cancer-testis antigen family, plays an important role in tumors, especially hematologic tumors; however, it is unknown whether SPAG6 plays a role in adult B-ALL. In this
-
Congenital dyserythropoietic anemia type II in a newborn with a novel compound heterozygous mutation in the SEC23B: a case report and review of the literature Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-21 Jiajia Zheng, Li Gao, Hu Liu, Peifang Xiao, Jun Lu, Jie Li, Shuiyan Wu, Shengqin Cheng, Xinni Bian, Zhizhuo Du, Lingjun Kong, Shaoyan Hu, Junjie Fan
-
FLT3 targeting in the modern era: from clonal selection to combination therapies Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-19 Vanessa E. Kennedy, Catherine C. Smith
-
Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-19
Abstract Patients with hemophilia A (PwHA) may have concurrent deficiency of representative anticoagulant proteins, protein (P)C, PS, and antithrombin (AT), which reduces bleeding frequency. However, emicizumab-driven hemostasis in PwHA with such thrombophilic potential remains unclarified. This study investigated the influence of natural anticoagulants on emicizumab-driven coagulation in HA model
-
Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-16 Kazuhito Suzuki, Tadahiro Gunji, Masaharu Kawashima, Hideki Uryu, Riku Nagao, Mamiko Momoki, Hiroki Yokoyama, Hiroto Ishii, Susumu Tanoue, Takeshi Saito, Kaichi Nishiwaki, Shingo Yano
-
Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-15 Keiji Nogami, Teruhisa Fujii, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Daisuke Nosaka, Tomomi Shimura, Yoshimasa Sugao, Kagehiro Amano
-
Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation Int. J. Hematol. (IF 2.1) Pub Date : 2023-12-12 Jun Nukui, Takayoshi Tachibana, Takuya Miyazaki, Masatsugu Tanaka, Kenji Matsumoto, Yoshimi Ishii, Ayumi Numata, Yuki Nakajima, Ayako Matsumura, Taisei Suzuki, Akihiko Izumi, Natsuki Hirose, Koji Yamamoto, Maki Hagihara, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima
-
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11) Int. J. Hematol. (IF 2.1) Pub Date : 2023-11-28 Kensuke Usuki, Shigeki Ohtake, Sumihisa Honda, Mitsuhiro Matsuda, Atsushi Wakita, Yuichiro Nawa, Ken Takase, Akio Maeda, Nobuo Sezaki, Hisayuki Yokoyama, Satoru Takada, Daiki Hirano, Tatsuki Tomikawa, Masahiko Sumi, Shingo Yano, Hiroshi Handa, Shuichi Ota, Hiroyuki Fujita, Katsumichi Fujimaki, Atsuko Mugitani, Kensuke Kojima, Tomohiro Kajiguchi, Ko Fujimoto, Norio Asou, Noriko Usui, Yuichi Ishikawa
-
Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia Int. J. Hematol. (IF 2.1) Pub Date : 2023-11-27 Ichiro Shiomi, Soichiro Nakako, Takahiko Nakane, Yumi Ogawa, Taku Araki, Yotaro Fujitani, Ryosuke Yamamura, Masayuki Hino, Hirohisa Nakamae
-
Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis Int. J. Hematol. (IF 2.1) Pub Date : 2023-11-21 Yuta Sakai, Yasuhiro Ikawa, Mika Takenaka, Kazuhiro Noguchi, Toshihiro Fujiki, Hiroko Ikeda, Taizo Wada